# CANCER OF UNKNOWN PRIMARY IN THE ERA OF PRECISION MEDICINE

**Friday 3 May 2019**

The Royal College of Physicians
London

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1 – Current Optimal Tissue Diagnostics for CUP</th>
<th>Chair: Harpreet Wasan</th>
</tr>
</thead>
<tbody>
<tr>
<td>0925 – 0940</td>
<td>State of the art immunohistochemistry for the diagnosis of tissue of origin: Royal College of Pathologists standard</td>
<td>John Schofield</td>
</tr>
<tr>
<td>0940 – 0955</td>
<td>Evolving morphomolecular pathology in the diagnosis of tissue of origin</td>
<td>Karin Oien</td>
</tr>
<tr>
<td>0955 – 1010</td>
<td>The usefulness and potential of the epigenetic/methylation assay (EPICUP) for tissue of origin diagnosis</td>
<td>Manel Esteller</td>
</tr>
<tr>
<td>1010 – 1030</td>
<td>Progress, accuracy and limitations of available molecular cancer classifier assays for tissue of origin diagnosis: review of various assays</td>
<td>Richard Tothill</td>
</tr>
<tr>
<td>1030 -1100</td>
<td>Comprehensive genomic profiling of CUP: therapeutic implications</td>
<td>Prasanth Reddy</td>
</tr>
</tbody>
</table>

**1100 – 1130 COFFEE**

**1130 - 1155** *Panel discussion with audience questions*. Diagnostic and Therapeutic importance of tissue of origin analysis and other biomarkers in CUP. Panellists: *Drs Schofield, Oien, Tothill, Esteller, Reddy, Cook*

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 2 Current Clinical and Translational Trials</th>
<th>Chair: Penny Schofield</th>
</tr>
</thead>
<tbody>
<tr>
<td>1155 – 1210</td>
<td>Update on UK studies including CUP-ONE, CUPEM &amp; 100k Genomes CUP GeCIP</td>
<td>Harpreet Wasan</td>
</tr>
<tr>
<td>1210 – 1225</td>
<td>The SUPER Australian study; selected updates and perceptions of CUP by medical oncologists, a national survey</td>
<td>Penny Schofield</td>
</tr>
</tbody>
</table>
Japanese phase II study of empiric chemotherapy versus site-directed therapy based on a molecular cancer classifier assay; Phase III GEFCAP 104 study; global view/background of CUPISCO study: importance and limitations regarding cup management

‘The Agony and the Efficacy’: UK Perspective on the CUPISCO Trial

Session 2 continued... Current Clinical and Translational Trials  Chair: Penny Schofield

US studies: Sarah Cannon retrospective CUP subsets, Phase II molecular classifier based site specific therapy; immune checkpoint blockers and MyPathway; NCI Match; ASCO Tapur

Discussion panel with audience questions: Panelists: Doctors Wasan, Krämer, Shiu, Cook, Reddy

Session 3 – Optimal management and focus on the future  Chair: Harpreet Wasan

Integration of a molecular cancer classifier and comprehensive molecular profiling in selected patients

Review of evolving technologies including liquid biopsies and circulating tumour cells

TEA

Whole genome sequencing and immune profiling

The Cancer Genome Atlas (TCGA) and the search for a CUP genetic/epigenetic signature

Debates: (10 minutes per speaker)

1. Comprehensive molecular profiling should be the preferred test rather than a molecular cancer site of origin classifier assay
   For: Prasanth Reddy. Against: Natalie Cook

2. CUP is a clinico-pathological syndrome of many specific cancer types with occult primaries, which have predictable responses to therapies, once classified.
   For: Alwin Krämer. Against: Harpreet Wasan

Audience and speakers’ discussion
Topic: Optimal management of CUP and future research priorities

Closing remarks
Drinks and poster prize award